Scarica l'app Stockscreener
5.27
0.57%
-0.03
Dopo l'orario di chiusura:
5.25
-0.02
-0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FGEN Giù?
Forum
Previsione
Precedente Chiudi:
$5.30
Aprire:
$5.27
Volume 24 ore:
19,466
Relative Volume:
0.49
Capitalizzazione di mercato:
$31.22M
Reddito:
$147.75M
Utile/perdita netta:
$-284.23M
Rapporto P/E:
-1.7986
EPS:
-2.93
Flusso di cassa netto:
$-317.54M
1 W Prestazione:
-3.13%
1M Prestazione:
-26.70%
6M Prestazione:
-60.19%
1 anno Prestazione:
-72.63%
Intervallo 1D:
$5.03
$5.4182
Intervallo di 1 settimana:
$4.85
$5.77
Portata 52W:
$4.50
$38.25
Fibrogen Inc Stock (FGEN) Company Profile
Nome
Fibrogen Inc
Settore
Industria
Telefono
415-978-1200
Indirizzo
350 BAY STREET, SAN FRANCISCO, CA
Confronta FGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
5.27 | 31.22M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | Downgrade | Stifel | Buy → Hold |
| 2023-06-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | Aggiornamento | Stifel | Hold → Buy |
| 2023-01-31 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-09-22 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-07-16 | Downgrade | Stifel | Buy → Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | Downgrade | Mizuho | Buy → Neutral |
| 2021-03-31 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-03-02 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-26 | Iniziato | Raymond James | Underperform |
| 2020-07-10 | Ripresa | Stifel | Buy |
| 2020-05-01 | Iniziato | Cowen | Market Perform |
| 2020-04-27 | Iniziato | BofA/Merrill | Neutral |
| 2019-05-29 | Ripresa | Goldman | Neutral |
| 2019-05-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | Iniziato | Piper Jaffray | Neutral |
| 2019-02-11 | Ripresa | Stifel | Buy |
| 2018-12-19 | Aggiornamento | Citigroup | Neutral → Buy |
| 2017-08-08 | Reiterato | Leerink Partners | Outperform |
| 2017-08-08 | Reiterato | Stifel | Buy |
| 2017-07-21 | Downgrade | Goldman | Buy → Neutral |
| 2017-07-11 | Iniziato | Jefferies | Buy |
| 2016-02-11 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
| 2015-12-04 | Iniziato | Citigroup | Buy |
| 2015-09-23 | Iniziato | Lake Street | Hold |
| 2015-07-29 | Iniziato | Citigroup | Buy |
| 2015-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2014-12-09 | Iniziato | Stifel | Buy |
Mostra tutto
Fibrogen Inc Borsa (FGEN) Ultime notizie
FibroGen (FGEN) Trading Halted Pending News Release | FGEN Stock News - GuruFocus
FibroGen Enters New Agreement with HiFiBiO - TipRanks
Fibrogen IncOn June 12 Enters Termination, Asset Transfer And License Agreement With Hifibio - MarketScreener
FibroGen (FGEN) Announces 1-for-25 Reverse Stock Split | FGEN St - GuruFocus
FibroGen to implement 1-for-25 reverse stock split; shares down 15% - MSN
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Adobe, RH And 3 Stocks To Watch Heading Into FridayAdobe (NASDAQ:ADBE), FibroGen (NASDAQ:FGEN) - Benzinga
FibroGen Announces 1-for-25 Reverse Stock Split | FGEN Stock New - GuruFocus
FibroGen Announces Reverse Stock Split Effective June 16 - TipRanks
FibroGen to Implement 1-for-25 Reverse Stock Split - marketscreener.com
FibroGen To Implement 1-for-25 Reverse Stock Split - Nasdaq
FibroGen, Inc. Announces 1-for-25 Reverse Stock Split Effective June 16, 2025 - Nasdaq
Fibrogen Announces 1-For-25 Reverse Stock Split - marketscreener.com
FibroGen Announces 1-for-25 Reverse Stock Split - GlobeNewswire
FibroGen's Massive 1-for-25 Reverse Split Cuts 101M Shares to 4MWhat Investors Must Know - Stock Titan
Millennium Management LLC Lowers Stock Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen expands board with biotech veteran Kauffman By Investing.com - Investing.com South Africa
FibroGen expands board with biotech veteran Kauffman - Investing.com Australia
FibroGen Amends Financing Agreement for Flexibility - TipRanks
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors | FGEN Stock News - GuruFocus
Fibrogen Appoints Michael Kauffman To Its Board Of Directors - marketscreener.com
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors - GlobeNewswire
FibroGen Strengthens Board with Velcade Developer: Key Move for Pipeline Advancement - Stock Titan
Squarepoint Ops LLC Takes Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
Two Sigma Advisers LP Has $465,000 Position in FibroGen, Inc. (NASDAQ:FGEN) - Defense World
FibroGen, Inc. (NASDAQ:FGEN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com - Defense World
FibroGen outlines $185M China divestiture and extended cash runway into 2027 while advancing prostate cancer pipeline - MSN
FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline By Investing.com - Investing.com South Africa
FibroGen First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
FibroGen Q1 2025 slides: China sale to extend cash runway amid revenue decline - Investing.com Australia
HC Wainwright Has Negative Outlook for FibroGen Q2 Earnings - Defense World
FibroGen’s Earnings Call: Strategic Gains Amid Revenue Woes - TipRanks
FibroGen (NASDAQ:FGEN) Earns Buy Rating from HC Wainwright - Defense World
FibroGen (FGEN) Boosts Sale Proceeds from Chinese Division - GuruFocus
FibroGen (FGEN) Receives Reaffirmed Buy Rating from HC Wainwrigh - GuruFocus
FibroGen, Inc. (NASDAQ:FGEN) Q1 2025 Earnings Call Transcript - Insider Monkey
FibroGen Inc earnings beat by $0.15, revenue fell short of estimates - Investing.com UK
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid ... - Yahoo Finance
FibroGen Inc (FGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Cost Management Amid Revenue Decline - GuruFocus
FibroGen Reports Q1 2025 Earnings and Strategic Updates - TipRanks
Earnings call transcript: FibroGen Q1 2025 sees revenue drop, stock rises - Investing.com Canada
FibroGen Q1 2025 Earnings Call Transcript - MarketBeat
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
FibroGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimates at $2.7M, EPS Misses with $0.16 Loss - GuruFocus
FibroGen Inc Reports Q1 2025 Earnings: Revenue Surpasses Estimat - GuruFocus
FibroGen: Q1 Earnings Snapshot - San Antonio Express-News
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
FIBROGEN INC SEC 10-Q Report - TradingView
Fibrogen Inc Azioni (FGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Fibrogen Inc Azioni (FGEN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):